Have You Experienced...
- Migratory joint pain (one knee this week, the other shoulder next)
- Drenching night sweats without obvious cause
- A flu-like illness that "started everything" months or years ago
- Air hunger, breath-holding, or unexplained chest tightness
- "Ice pick" headaches that come and go
- Stretch-mark-like skin striae you don't remember getting
- A known or suspected tick bite, with or without bullseye rash
- Standard Lyme tests came back negative but symptoms persist
- Got antibiotics early but never fully recovered
Quick Answer
Lyme rarely travels alone. Tick-borne co-infections (Bartonella, Babesia, Ehrlichia, Anaplasma) and reactivated viruses (EBV, HHV-6, CMV) often drive the chronic phase more than Borrelia itself. Standard two-tier ELISA testing misses 30–50% of chronic cases. Specialized PCR, T-cell, and ImmunoBlot testing changes the diagnostic picture — and treating the full infection picture, not just Lyme, is what produces durable recovery.
The Co-Infections That Actually Drive Symptoms
Most patients who carry "chronic Lyme" actually carry an infection cocktail. Treating only Borrelia without addressing the co-infections is the most common reason patients don't fully recover even after years of antibiotics.
Borrelia (Lyme)
The marquee infection — but standard two-tier testing misses up to 40% of chronic cases because antibodies wane and the bacteria can hide in tissue, biofilm, and intracellular forms.
Bartonella
One of the most common drivers of neuropsychiatric symptoms in our practice — sudden-onset anxiety, OCD-like rumination, "ice pick" headaches, foot pain on waking, and characteristic stretch-mark-like striae.
Babesia
A protozoan parasite carried by the same ticks as Lyme. Hallmarks: air hunger and sighing, drenching night sweats, and unexplained anxiety that reads as panic disorder on standard psychiatric exams.
Ehrlichia & Anaplasma
Drive severe headache, fevers, and profound muscle pain. Often missed on standard ELISA; PCR during acute phase is more reliable.
Reactivated viruses (EBV, HHV-6, CMV)
Common after the immune stress of acute tick-borne illness. Sustain chronic fatigue and the "wired and tired" state that persists long after antibiotics.
Mycoplasma
Stealth bacterial infection that frequently co-travels with tick-borne disease and contributes to fatigue, joint pain, and respiratory symptoms.
Why Standard Testing Misses It
The CDC two-tier algorithm (ELISA followed by Western blot only if ELISA is positive) was designed for surveillance, not patient diagnosis. It misses chronic cases for several reasons:
- Antibody response wanes over months and years
- Borrelia can suppress immune signaling — many chronic patients can't mount the expected antibody response
- The Western blot CDC criteria omit the most specific bands
- Co-infections require completely separate panels — they aren't picked up by Lyme testing
Suspect chronic Lyme or co-infections?
Most patients we see have already been told they're "negative." A real exposure history is where we start.
Better Testing
- IGeneX Western Blot and ImmunoBlot — improved sensitivity over CDC criteria, reports all bands
- Vibrant Tickborne 2.0 — combines serology, PCR, and co-infection screening in one panel
- T-cell-based testing (LymeSpot, EliSpot-LTT) — measures active immune response to Borrelia rather than just antibody history
- Co-infection panels — separate PCR + antibody testing for Bartonella, Babesia, Ehrlichia, Anaplasma, Mycoplasma
- Viral reactivation panel — EBV early antigen, EBNA, HHV-6 IgG/IgM, CMV — interpreted by an environmental medicine specialist, not as routine "old immunity"
A Real Treatment Plan
Antibiotic monotherapy frequently fails in chronic disease because biofilms protect the organisms, immune dysfunction persists, and co-infections require different agents. Effective treatment is layered and sequenced over months:
- Stabilize first. Calm mast cell activation and inflammation. Open drainage pathways. Many patients can't tolerate antimicrobials until this step is done.
- Address co-infections in the right order. Bartonella first if present, then Babesia, then Borrelia. Order matters — treating Lyme first while Bartonella is active often causes severe Herxheimer reactions without progress.
- Disrupt biofilms. Specific enzymes and binders break down the protective matrices that hide the bacteria from antibiotics.
- Targeted antimicrobials. Pharmaceutical and/or botanical, matched to the specific organisms — not a one-size protocol.
- Restore the host. Mitochondrial repair, gut restoration, autonomic regulation, sleep architecture.
Framework overview
Chronic microbial drivers rarely come alone. The patient with persistent EBV often has gut dysbiosis. The patient with chronic Lyme often has Bartonella and Babesia. The framework is built around what we actually find, not what's easy to test for.
What this driver domain covers
Microbes is the broadest domain in the 5M Model. It encompasses several categories of chronic microbial contribution to illness: chronic tick-borne infections (Lyme, Bartonella, Babesia, and the less common Anaplasma, Ehrlichia, Rickettsia); chronic parasitic infections (both helminthic and protozoal); chronic viral reactivation (Epstein-Barr virus, cytomegalovirus, and the post-acute sequelae of SARS-CoV-2 — Long COVID and post-vaccine syndromes); and gut microbiome dysfunction (dysbiosis, small intestinal bacterial overgrowth, fungal overgrowth).
The unifying clinical principle is that chronic microbial drivers — whether bacterial, viral, parasitic, or compositional imbalances of normal flora — produce systemic effects through sustained immune activation, direct cellular dysfunction, and downstream metabolic and inflammatory consequences. Patients rarely present with one isolated chronic microbial issue. They present with patterns, and recognizing the patterns is the diagnostic work.
Why this domain is so frequently missed
Mainstream infectious disease medicine is built around acute infection — identifying the organism, treating it, monitoring for resolution. The infrastructure for evaluating and treating chronic, persistent, or post-infectious microbial contribution to illness is much less developed. Several specific gaps recur:
Diagnostic testing for chronic infections has well-documented limitations. Standard Lyme serology misses a significant percentage of cases, particularly in chronic disease. Bartonella testing is notoriously poor. Babesia detection requires specific approaches that aren't part of routine evaluation. Standard stool studies miss many parasitic infections, particularly in chronic and low-burden cases.
The clinical framework for post-infectious illness is underdeveloped. Patients with persistent symptoms after acute Lyme, after mononucleosis, after COVID-19, or after other infections are often told there's nothing more to investigate. The biological mechanisms — persistent infection, persistent immune dysregulation, mitochondrial sequelae, mast cell activation — receive limited clinical attention outside specialty settings.
Chronic viral reactivation in immunocompetent patients is rarely evaluated. EBV titers suggesting active reactivation are often dismissed as incidental. CMV is treated only in immunocompromised patients despite emerging research on its role in chronic inflammation and accelerated immune aging. The clinical significance of these patterns in patients with otherwise unexplained chronic illness is underappreciated.
Gut microbiome dysfunction is evaluated narrowly. Standard gastroenterology focuses on identifiable structural disease. The broader role of microbiome composition in immune function, neurological function, hormone metabolism, and inflammation is acknowledged in research but rarely translated into clinical evaluation.
The clinical patterns iHeal looks for
Multi-system chronic symptoms following an identifiable infectious event — a tick bite years ago, a severe case of mononucleosis, a COVID-19 infection, an episode of travel-associated parasitic exposure. Patterns of waxing and waning symptoms suggestive of intermittent microbial activity. Lymphadenopathy, low-grade fevers, night sweats, or other findings suggesting active immune engagement. Co-occurring conditions that cluster with chronic microbial drivers — fatigue, cognitive symptoms, dysautonomia, mast cell activation patterns, gut dysbiosis.
The diagnostic work involves both expanded testing — using specialty laboratories where appropriate — and clinical correlation. Testing alone doesn't establish chronic microbial drivers; testing in the context of consistent clinical pattern, exposure history, and treatment response does.
How chronic microbial drivers interact with other domains
Microbes rarely operate in isolation in the 5M Model. The patient with chronic Lyme almost always has downstream mast cell activation and mitochondrial dysfunction. The patient with significant gut dysbiosis often has secondary nutrient deficiencies, hormone metabolism disruption, and immune dysregulation that look like separate problems. The patient with chronic EBV reactivation often has co-occurring HPA axis dysregulation, fatigue patterns indistinguishable from ME/CFS, and increased susceptibility to other infections.
Treating chronic microbial drivers in isolation — antibiotics for Lyme without addressing mast cell activation, antifungals for SIBO without addressing what's allowing recurrence, antivirals for EBV without addressing the immune dysregulation that's allowing reactivation — produces partial responses that don't last. The framework approach is to identify the microbial drivers, address them appropriately, and simultaneously support the response domains that have been activated.
The condition pages that go deeper
Specific clinical detail on each major category of chronic microbial driver lives on dedicated condition pages: Tick-Borne Disease (Lyme, Bartonella, Babesia); Long COVID and Post-Vaccine Syndromes (Spike Protein-Related Illness); Chronic Viral Reactivation (EBV and CMV); Parasites: Worms and Helminthic Infections; Parasites: Protozoa and Cystic Parasites; SIBO and SIFO; and Gut Dysbiosis. Each goes deeper than this framework page can, with the specific clinical patterns, testing approaches, and treatment considerations relevant to that category.
Deeper clinical content
Frequently Asked Questions
Yes. Standard two-tier ELISA testing misses 30–50% of chronic cases. Antibody response wanes, Borrelia can suppress immune signaling, and the CDC band criteria are too narrow. Specialized testing — ImmunoBlot, T-cell-based assays, PCR — frequently identifies active infection in patients with "negative" standard tests.
Yes. Roughly half of patients with confirmed Lyme don't recall a tick bite, and only 60–70% develop a bullseye rash. Nymphal ticks are smaller than a poppy seed and easily missed. Other vectors (mosquitoes, biting flies) are being investigated for Borrelia transmission as well.
Several reasons: biofilms protect the bacteria from circulating antibiotics, intracellular and persister forms aren't killed by standard regimens, co-infections require different drugs, and immune dysfunction from the infection itself prevents clearance even when bacteria are reduced. A layered protocol that addresses biofilms, co-infections, and immune support is what works in chronic disease.
Most patients see meaningful improvement within 3–6 months and durable remission within 12–24 months. Longer-duration illness and heavier co-infection load take longer. We re-test to confirm progress rather than treating indefinitely.